[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 61, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1032768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 61, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 735515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 57, "title": "Executive VP & CFO", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kristina  Engeseth", "title": "VP and Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 56, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 13.29, "open": 13.0548, "dayLow": 12.81, "dayHigh": 13.21, "regularMarketPreviousClose": 13.29, "regularMarketOpen": 13.0548, "regularMarketDayLow": 12.81, "regularMarketDayHigh": 13.21, "beta": 2.183, "forwardPE": -1.0498793, "volume": 39974, "regularMarketVolume": 39974, "averageVolume": 20433, "averageVolume10days": 29322, "averageDailyVolume10Day": 29322, "marketCap": 41868968, "fiftyTwoWeekLow": 8.7, "fiftyTwoWeekHigh": 30.0, "priceToSalesTrailing12Months": 5.255299, "fiftyDayAverage": 12.2962, "twoHundredDayAverage": 17.096424, "currency": "USD", "enterpriseValue": -4249051, "floatShares": 2372749, "sharesOutstanding": 3072410, "sharesShort": 12579, "sharesShortPriorMonth": 9939, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.20069, "heldPercentInstitutions": 0.61575, "shortRatio": 0.86, "shortPercentOfFloat": 0.0068, "impliedSharesOutstanding": 79902600, "bookValue": 10.914, "priceToBook": 1.195712, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -75735000, "trailingEps": -14.5, "forwardEps": -12.43, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": -0.533, "enterpriseToEbitda": 0.046, "52WeekChange": -0.39140534, "SandP52WeekChange": 0.24059486, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ALGS", "underlyingSymbol": "ALGS", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "firstTradeDateEpochUtc": 1602855000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "bbc2c389-779c-3f10-ac5a-f071b0904bd5", "messageBoardId": "finmb_581475891", "gmtOffSetMilliseconds": -14400000, "currentPrice": 13.05, "targetHighPrice": 175.0, "targetLowPrice": 75.0, "targetMeanPrice": 108.33, "targetMedianPrice": 75.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 94536000, "totalCashPerShare": 15.335, "ebitda": -91565000, "totalDebt": 9837000, "quickRatio": 4.012, "currentRatio": 4.226, "totalRevenue": 7967000, "debtToEquity": 14.632, "revenuePerShare": 1.648, "returnOnAssets": -0.53971, "returnOnEquity": -1.10672, "freeCashflow": -50269500, "operatingCashflow": -85233000, "revenueGrowth": -0.846, "operatingMargins": -24.89538, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-29"}]